Clinical outcome of proton therapy for patients with chordomas.

ABSTRACT:

Purpose

To investigate the clinical outcome of proton therapy (PT) in patients with chordoma.

Materials and methods

Fifty-eight patients with chordoma treated with PT between June 2007 and December 2015 at the National Cancer Center, Korea, were retrospectively analyzed. The median total dose was 69.6 cobalt gray equivalent (CGE; range, 64.8 to 79.2 CGE). Local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and diseasespecific survival (DSS) rates were calculated by the Kaplan-Meier method.

Results

With the median follow-up of 42.8 months (range, 4 to 174 months), the 5-year LPFS, DMFS, OS, and DSS rates were 87.9%, 86.7%, 88.3%, and 92.9%, respectively. The tumor location was associated with the patterns of failure:

SUBMITTER: Youn SH 

PROVIDER: S-EPMC6226136 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature